Global Peptide Based Infection Therapeutics Market expected to Grow US$ 1.5 Bn till 2022

Fact.MR Fact.MR

Dublin 2, Ireland, 2018-Jun-05 — /EPR Network/ — Recently, a novel report developed using proven research methodologies at the headquarters of Fact. MR has identified various prominent factors and trends prompting market growth of peptide based infection therapeutics s market. The study is titled as Peptide Based Infection Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022”, which deeply analyses the global market trends, with historical data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) during the mentioned forecast of 2017-2022. For the benefit of the readers, the report concludes with a special focus on the detailed profiles of the major vendors in the global peptide based infection therapeutics market.

Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=188

Peptide therapeutic agents are novel solutions to treat infectious diseases. The peptide based infection therapeutics market is impacted by factors such as higher investment in healthcare industry, advancements in technologies, increase in biotech and pharmaceutical companies, the need for peptides to treat infections owing to the various advantages offered by peptides such as safety, reliability, stability, higher efficacy, cost effectiveness and easy synthesis due to small size, rising developments in drug discovery and the rising foreign direct investment in emerging economies. All the aspects influence the global peptide based infection therapeutics market in a positive way. North America region is expected to be the most lucrative region for the global peptide based infection therapeutics market.

The global peptide based infection therapeutics market is anticipated to show a value a shade less than US$ 1.5 Bn and expected to grow at a robust rate during the period of forecast.

4 Forecast Highlights on Global Peptide Based Infection Therapeutics Market

1. North America expected to show higher market attractiveness and domination over other regions in terms of market share by revenue. It has a higher value share and is poised to grow at a higher growth rate to reflect a CAGR of 8.4% throughout the forecast period, 2017 to 2022

2. Asia-Pacific excluding Japan (APEJ) shows the highest growth rate and poised to register a CAGR of 8.7% during the period of forecast, owing to rapid development and higher foreign direct investment in this region. Following APEJ, Europe region also reflects good rate of growth in the global peptide based infection therapeutics market

3. By drug class, telaprivir shows higher market share by revenue as compared to boceprevir. However, boceprivir shows a higher growth rate to reflect a CAGR of 8.2% during the period of forecast. It can be said that, even though telaprevir segment has a market share which is almost one and a half times than that of  boceprevir, the boseprivir segment, could match the market share at this high growth rate post 2022, a market observation which would depend on the current growth rate of boceprivir and its consistency through 2017 to 2022 and even beyond

4. The online pharmacies segment by distribution channel shows the fastest growth rate and is poised to reflect a CAGR of 9.2% throughout the period of forecast of 2017 to 2022. Yet, this segment shows less market share by revenue as compared to other segments.

Browse Full Report with TOC- https://www.factmr.com/report/188/peptide-based-infection-therapeutics-market

APEJ to Show Tremendous Activity as Compared to Europe

The Asia-Pacific excluding Japan (APEJ) region is expected to show a rapid growth rate and is expected to register a CAGR of 8.7% during the period of forecast. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods and technologies to better the health of the patients and enhance patient outcome. Following Asia-Pacific excluding Japan (APEJ) region, Europe regions also shows good growth rate in the global peptide based infection therapeutics market.

Domination of North America in the Peptide Based Infection Therapeutics Market

With respect to the global peptide based infection therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share by revenue and is poised to grow at a higher growth rate to register a CAGR during the period of forecast. North America shows higher market attractiveness; this growth mainly attributed to the higher investment in the healthcare industry along with rapid technological developments. Latin America and Middle East and Africa (MEA) regions show relatively slow growth rate as compared to North America region and a fairly less market share and this trend is anticipated to continue during the period of forecast, 2017 to 2022.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of the global peptide based infection therapeutics market through 2022, which include Vertex Pharmaceuticals Incorporated, Merck & Co., Inc. and Parchem Fine & Specialty Chemicals.

Request Methodology of the Report- https://www.factmr.com/connectus/sample?flag=RM&rep_id=188

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized  Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com
Web: https://www.factmr.com/
follow us in Linkedin: https://www.linkedin.com/company/factmr/

Matched content

Editor’s pick

Express Press Release Distribution